CTRI/2022/11/047188尚未招募1 期
A double blind, balanced, randomized, two-treatment, two-sequence, two-period, single dose, cross over, pharmacokinetic and pharmacodynamic bioequivalence study of GEN1503PR (Insulin Aspart (r-DNA origin) Injection) 100 U/mL of GeneSys Biologics Pvt. Ltd. Hyderabad, India and NovoRapid® (Insulin Aspart (r-DNA origin) Injection) 100 U/mL of Novo Nordisk, in healthy adult, male human subjects using Euglycemic clamp technique under fasting conditions
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Healthy human subjects between 18-45 years of age.
- •2. Subjects able to communicate effectively.
- •3. Normal range for OGTT.
- •4. Truly voluntarily participation.
- •5. Subjects willing to give written informed consent and adhere to all the requirements of this protocol.
- •6. Body mass index in the range of 18.5 to 24.9 kg/m2 (weight should be >= 50 Kg).
- •7. Normal 12-lead ECG
- •8. Normal chest X-ray
- •9. Normal laboratory parameters
- •10. Absence of disease markers of HIV 1 & 2, hepatitis B & C virus and VDRL
- •11. Subject willing to abstain from all kinds of alcoholic beverages, smoking, and caffeine/xanthine containing foods or beverages from 72.00 hours before admission till the last post-dose blood sample collection in each study period.
排除标准
- •1. Subjects having history of contraindication or hypersensitivity (e.g., anaphylaxis) to Insulin
- •or related class of drugs will be excluded from the study.
- •2. A history or presence of significant asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs.
- •3. History or presence of diabetes, migraine, hypertension, cardiovascular, pulmonary, endocrine, immunological, hepatic, renal, hematopoietic, gastrointestinal, ongoing infectious diseases, or any other significant abnormality as evidenced by medical history and physical examination or according to the opinion of the physician.
- •4. History or presence of gastrointestinal (GI) inflammation, bleeding, ulceration, and perforation of the stomach, small intestine, or large intestine.
- •5. History or presence of significant systemic diseases, seizures, psychiatric disorders, neurological disorders.
- •6. History of diabetic ketoacidosis
- •7. History of hypoglycaemia (symptoms include low pulse rate, watering of extremities, dizziness, weakness and sometimes fainting)
- •8. History or evidence of exfoliative dermatitis, Stevens - Johnson syndrome (SJS), and toxic epidermal necrolysis (TEN).
- •9. Any known enzyme inducing or inhibiting drug taken within 30 days before the study.
- •10. Participation in a drug research study within 90 days prior to dosing of this study.
- •11. Blood loss or whole blood donation within 90 days prior to drug administration.
- •12. Consumption of high caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/beedies/cigars per day).
- •13. History of addiction to any recreational drug or drug dependence.
- •14. An unusual or abnormal diet, for whatever reason within 48.00 hours prior to admission of each period, e.g., fasting due to religious reasons.
- •15. History of dehydration from diarrhea, vomiting or any other reason within a period of 48.00 hours prior to study admission of each period.
- •16. Positive results for drugs of abuse (benzodiazepines, cocaines, opioids, amphetamines,
- •cannabinoids and barbiturates) in urine during the admission of each study period.
- •17. Positive results for alcohol consumption during the admission of each study period.
- •18. History of pre-existing bleeding disorder.
- •19. Difficulty with donating blood.
- •20. Difficulty in swallowing oral solids like tablets / capsules.
- •21. Blood pressure on the day of admission of each study period
- •a. Systolic blood pressure less than 90 mm Hg or more than 140 mm Hg.
- •b. Diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg.
- •22. Pulse rate less than 60 beats/minute or more than 100 beats/minute on the day of admission of each study period.
- •23. History of alcohol abuse and/or dependence within six months of the screening visit or History of drug abuse or use of illegal drugs within 90 days prior to dosing of this study.
研究者
相似试验
已完成
不适用
PHARMACOKINETIC, PHARMACODYNAMIC BIOEQUIVALENCE STUDY ON VB70G(INSULIN GLARGINE INJECTION) 100 IU/ML - FASTINGCTRI/2022/08/044806Virchow Biotech Private Limited40
尚未招募
1 期
Comparative bioavailability/ bioequivalence study of Lutein formulations - Product C and Product D (Lutein 20 mg/capsule) supplementation in healthy, adult humans, after receiving high-fat, high-calorie breakfast.CTRI/2018/08/015403Mr Abhijeet Morde
尚未招募
1 期
To Compare the bioavailability of Lutein formulations - Product A and Product B (Lutein 10 mg/Zeaxanthin 2 mg per capsule) supplementation in healthy, adult human subjects under fed conditions.CTRI/2019/11/022082Mr Abhijeet Morde
尚未招募
1 期
Comparative bioavailability/ bioequivalence study of Lutein formulations - Product A and Product B (Lutein 20 mg/capsule) supplementation in healthy, adult humans, after receiving high-fat, high-calorie breakfast.CTRI/2018/08/015507Mr Abhijeet Morde
尚未招募
1 期
Comparing the Lutein formulations - Product A and Product B (Lutein 25 mg/capsule) supplementation in healthy, adult humans, after receiving high-fat, high-calorie breakfast.CTRI/2018/01/011167Mr Abhijeet Morde